Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0001288

Salbutamol hemisulfate salt

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Salbutamol hemisulfate salt, α1-[(tert-Butylamino)methyl]-4-hydroxy-1,3-benzenedimethanol hemisulfate salt, Albuterol sulfate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C13H21NO3 · 0.5H2SO4
Numéro CAS:
51022-70-9
Poids moléculaire :
288.35
Numéro MDL:
MFCD00055200
Code UNSPSC :
41116107
ID de substance PubChem :
329831344
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

albuterol, salbutamol

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

−20°C

Chaîne SMILES 

OS(O)(=O)=O.CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CC(C)(C)NCC(O)c2ccc(O)c(CO)c2

InChI

1S/2C13H21NO3.H2O4S/c2*1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15;1-5(2,3)4/h2*4-6,12,14-17H,7-8H2,1-3H3;(H2,1,2,3,4)

Clé InChI

BNPSSFBOAGDEEL-UHFFFAOYSA-N

Informations sur le gène

human ... ADRB2(154)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Salbutamol sulfate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

PHR1053

Albuterol sulfate, Pharmaceutical Secondary Standard; Certified Reference Material

S0150000

Salbutamol hemisulfate salt, European Pharmacopoeia (EP) Reference Standard

Y0000034

Salbutamol impurity G, European Pharmacopoeia (EP) Reference Standard

Y0000030

Salbutamol impurity B, European Pharmacopoeia (EP) Reference Standard

Y0000031

Salbutamol impurity F, European Pharmacopoeia (EP) Reference Standard

Y0000071

Salbutamol impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000032

Salbutamol impurity I, European Pharmacopoeia (EP) Reference Standard

S0100000

Salbutamol, European Pharmacopoeia (EP) Reference Standard

Y0001186

Salbutamol impurity J, European Pharmacopoeia (EP) Reference Standard

1012633

Salbutamol hemisulfate salt, United States Pharmacopeia (USP) Reference Standard

1358784

Levalbuterol hydrochloride, United States Pharmacopeia (USP) Reference Standard

1012600

Salbutamol, United States Pharmacopeia (USP) Reference Standard

1012644

Albuterol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1012655

Albuterol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1012689

Albuterol Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP451

Salbutamol, British Pharmacopoeia (BP) Reference Standard

BP302

Salbutamol hemisulfate salt, British Pharmacopoeia (BP) Reference Standard

PHR1960

Salbutamol Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2040

Albuterol Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1961

Salbutamol Impurity G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1962

Salbutamol impurity I, Pharmaceutical Secondary Standard; Certified Reference Material

BP712

Salbutamol aldehyde impurity, British Pharmacopoeia (BP) Reference Standard

BP192

2-tert-Butylamino-1-(4-hydroxy-3-methylphenyl)ethanol sulfate, British Pharmacopoeia (BP) Reference Standard

BP852

Salbutamol impurity B, British Pharmacopoeia (BP) Reference Standard

BP704

Salbutamol ketone impurity, British Pharmacopoeia (BP) Reference Standard

PHR2106

4-[2-[(1,1-Dimethylethyl)amino]ethyl]-2-methylphenol, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9050

4-[2-(tert-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol, reference material, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9071

4-[2-[Benzyl(tert-butyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

1012564

Albuterol Related Compound I, United States Pharmacopeia (USP) Reference Standard

PHR2332

Methyl5-[2-[benzyl(tert-butyl)amino]acetyl]-2-hydroxybenzoate hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H317,H351,H361fd

Classification des risques

Carc. 2 - Repr. 2 - Skin Sens. 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

Salbutamol

Sigma-Aldrich

S8260

Salbutamol

B Padhukasahasram et al.
The pharmacogenomics journal, 14(4), 365-371 (2014-01-15)
Inhaled short-acting beta-agonist (SABA) medication is commonly used in asthma patients to rapidly reverse airway obstruction and improve acute symptoms. We performed a genome-wide association study of SABA medication response using gene-based association tests. A linear mixed model approach was
Helgo Magnussen et al.
The New England journal of medicine, 371(14), 1285-1294 (2014-09-10)
Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.
Dwight D Koeberl et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 28(5), 2171-2176 (2014-01-21)
Effective dosages for enzyme replacement therapy (ERT) in Pompe disease are much higher than for other lysosomal storage disorders, which has been attributed to low cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle. We have previously demonstrated the benefit of increased
Todd A Florin et al.
JAMA pediatrics, 168(7), 664-670 (2014-05-28)
Acute bronchiolitis is the most frequent lower respiratory tract infection in infants, yet there are no effective therapies available. Current evidence is unclear about the role of hypertonic saline (HS) for the acute treatment of bronchiolitis. To determine whether nebulized
Susan Wu et al.
JAMA pediatrics, 168(7), 657-663 (2014-05-28)
Bronchiolitis is one of the most common and costly respiratory diseases in infants and young children. Previous studies have shown a potential benefit of nebulized hypertonic saline; however, its effect in the emergency department (ED) setting is unclear. To compare
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique